-+ 0.00%
-+ 0.00%
-+ 0.00%

Chromocell Therapeutics Q1 GAAP EPS $(0.32) Misses $(0.31) Estimate

Benzinga·05/13/2025 21:58:54
Listen to the news
Chromocell Therapeutics (AMEX:CHRO) reported quarterly losses of $(0.32) per share which missed the analyst consensus estimate of $(0.31) by 3.23 percent. This is a 41.82 percent increase over losses of $(0.55) per share from the same period last year.